Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced it has received a Canadian patent for its cancer vaccine.
The newly issued patent follows the previous issuance of a US patent in October 2022 and comes with a pending European Union patent.
This patented technology safeguards Theralase’s photo dynamic compound (PDC) technology in administering cancer vaccines, specifically designed to target and eliminate cancer cells.
The approach involves extracting a sample of the patient's cancer, treating it with Theralase PDCs, and subsequently activating the PDCs with either light or radiation. The treated cancer cells are then reintroduced into the patient intravenously, effectively programming the immune system to identify, attack, and eradicate the specific cancer.
Dr Arkady Mandel, Chief Scientific Officer of Theralase, and the inventor of the patent, emphasized the potential impact of this technology on patients suffering from blood-related cancers, including leukemia, lymphoma, and myeloma.
"Our primary focus has been on the research and development of technology to destroy solid-core tumours, such as bladder, brain and lung cancers; however, this new patent allows the company the opportunity to explore the treatment of various liquid cancers."
Roger DuMoulin-White, President and Chief Executive Officer of Theralase, expressed enthusiasm about the company's expanding prospects.
"The possibilities and opportunities of our PDC technology continue to grow at a rapid pace," he said.
DuMoulin-White told investors that Theralase “plans to become properly financed this year through various equity and debt instruments to allow the company the opportunity to commence new clinical studies focused on the destruction of both solid-core and liquid cancers."
Theralase's pipeline includes a Phase II registration clinical study for bladder cancer slated for completion in 2026, along with plans to initiate a Phase Ib clinical study for brain cancer and lung cancer in 2024, pending completion of a toxicology analysis.
Theralase granted Canadian patent for cancer vaccine technology